Herantis Pharma announces an internationally renowned

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Herantis Pharma announces an internationally renowned Scientific Advisory Board with Professor Jonathan Knowles as Chairman

Herantis Pharma announces an internationally renowned Scientific Advisory Board with Professor Jonathan Knowles as Chairman Herantis Pharma Plc Company release 18 March 2015 at 10:00 am Herantis Pharma Plc has formed a Scientific Advisory Board of internationally renowned drug development professionals. The Scientific Advisory Board or its subgroups will convene frequently or its members may support the drug development programs of Herantis through other means. Professor Jonathan Knowles has accepted his nomination as Chairman of the Scientific Advisory Board. "Scientific research in Finland is outstanding in a number of fields of medicine", says professor Knowles. "It is important that there are focused approaches to develop the results of this innovative research into products that will benefit patients. I hope that the Herantis Scientific Advisory Board will help further strengthen this collaboration between industry and academia in the interests of patients around the world." Professor Knowles has been a Board member of Herantis since 2009. Previously he has served as President of group research and executive committee member at Roche, member of the Genentech Board, the founding Chairman of the EU's Innovative Medicines Initiative (IMI), and more recently as FiDiPro Professor at FIMM, University of Helsinki, visiting professor at Oxford University and professor emeritus at EPFL (École Polytechnique Fédérale de Lausanne). He was awarded the Scrip's Lifetime Achievement Award in 2010 for his long academic and industry career which has been distinguished by his passion for personalized medicine. Four other members have been nominated in the Scientific Advisory Board of Herantis: Academy Professor Kari Alitalo, Director of the Centre of Excellence on Translational Cancer Biology in the Faculty of Medicine of the University of Helsinki. Professor Alitalo is one of the world's leading researchers in oncogenes and mechanisms of angiogenesis and e.g. member of the National Academy of Sciences of the USA. He has received several international science prizes including the In-Bev Baillet Latour Health Prize and the Dr. A.H.Heineken Prize for Medicine by the Royal Netherlands Academy of Arts and Sciences. Professor Seppo Kaakkola, PhD and medical doctor specialized in Parkinson's Disease where he has made a significant career as a widely published researcher and in drug development as well as voluntary work in Parkinson's Disease patient associations. Professor Kaakkola is Chief Physician of the neurology department of the Helsinki University Central Hospital. Professor Mart Saarma, Long-time director of the Institute of Biotechnology of the University of Helsinki and one of the most valued researchers of neurotrophic factors in the world. Professor Saarma has been awarded several international science prizes including the Nordic Science Prize by Lundbeck Foundation. He is a member of e.g. the EMBO Council and the Estonian Academy of Sciences, and was appointed Vice President of the European Research Council since 2015. Doctor Alan Whone, Senior researcher at the University of Bristol specialized in motor dysfunctions such as Parkinson's Disease, and Consulting Neurologist at the Frenchay Hospital in Bristol, UK. Among Dr. Whone's current research projects are clinical studies related to Deep Brain Stimulation and neurotrophic factors for the treatment of Parkinson's Disease. Herantis Pharma intends to continue to invite both permanent and temporary members in its Scientific Advisory Board based on the needs in the company's development programs. Further information: Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445 Company web site: www.herantis.com Certified Advisor: UB Capital Oy, telephone: +358 9 2538 0225 About Herantis Pharma Plc Herantis Pharma Plc is a pharmaceutical company specialised in new drug research and development. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson's disease, and secondary lymphedema. We believe our drugs are the first or best in their class and have the potential to change treatment strategies of diseases. The shares of Herantis Pharma Plc are listed on the First North Finland marketplace run by NASDAQ Helsinki stock exchange. [HUG#1900829]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Microinsurance Market Expected to Surpass $11 Billion by 2034

Updated Category News Views 137

Growth Trajectory of the Global Microinsurance Market The microinsurance market is witnessing remarkable transformation as consumer demands shift towards financial inclusion, coupled with increasing awareness of the myriad advantages insurance provides. This positive trend is fueled by government initiatives aimed at regulation and expansion of microinsurance offerings,...

Continue Reading
Ormat Technologies Launches Secondary Stock Offering

Updated Category News Views 188

Ormat Technologies Launches Secondary Stock Offering Ormat Technologies, Inc. (NYSE: ORA), renowned for its innovative geothermal and renewable energy solutions, recently announced an exciting development in the investment realm—the initiation of an underwritten secondary offering. This offering encompasses a total of 3,700,000 shares of common stock on behalf of ORIX...

Continue Reading
MongoDB Executive Share Transactions Highlight Growth Potential

Updated Category News Views 132

Insights from MongoDB Executive Share Transactions Cochran Hope F, a director at MongoDB, Inc. (NASDAQ: MDB), recently made notable moves with the company's Class A Common Stock, and these transactions were disclosed in the latest SEC filings. This activity has attracted attention from investors. In September, the director sold 1,174 shares at $224.38 each, which brought...

Continue Reading
Essential Guidance for Navigating Hurricane Travel Risks

Updated Category News Views 69

Essential Guidance for Navigating Hurricane Travel Risks Hurricane season brings with it the potential for severe weather that can disrupt travel plans and lead to significant financial losses. As storms like Hurricane Helene have shown, the impact can be widespread, devastating homes and infrastructure, particularly in the southeastern regions. During these turbulent...

Continue Reading
Ascend Performance Materials Launches High-Purity Production

Updated Category News Views 279

Ascend Performance Materials Starts High-Purity Acrylonitrile Production Ascend Performance Materials has recently announced an exciting new phase in its production capabilities. The company is now producing high-purity acrylonitrile at its Chocolate Bayou facility. This advancement comes after the successful installation and commissioning of state-of-the-art purification...

Continue Reading